107 related articles for article (PubMed ID: 3231516)
1. Restorative effect of MDP-Lys (L18) on leukopenia of cancer patient treated with radiotherapy.
Okawa T; Kikuchi Y; Watarai J; Dokiya T; Tanaka T; Saito Y; Hirokawa Y; Takegawa Y; Hata K
Nihon Igaku Hoshasen Gakkai Zasshi; 1988 Apr; 48(4):514-22. PubMed ID: 3231516
[No Abstract] [Full Text] [Related]
2. Restorative activity of muroctasin on leukopenia associated with anticancer treatment.
Tsubura E; Nomura T; Niitani H; Osamura S; Okawa T; Tanaka M; Ota K; Nishikawa H; Masaoka T; Fukuoka M
Arzneimittelforschung; 1988 Jul; 38(7A):1070-4. PubMed ID: 3190800
[TBL] [Abstract][Full Text] [Related]
3. [Restorative effect of muroctasin; MDP-Lys (L18) [DJ-7041] on leukopenia in urogenital cancer patients treated with chemotherapy].
Oishi K; Takeuchi H; Yoshida O; Nakagawa K; Fukuyama T; Okamoto K; Kihara Y; Okuno H; Shirahase T; Tomoyoshi T
Hinyokika Kiyo; 1989 Mar; 35(3):527-36. PubMed ID: 2660519
[TBL] [Abstract][Full Text] [Related]
4. Restorative effect of muroctasin on leukopenia caused by anticancer chemotherapy in lung cancer. Comparative study by envelope method.
Fukuoka M; Takada M; Takifuji N; Sakai N; Ryu S; Masuda N; Matsui K; Negoro S; Kusunoki Y; Tubura E
Arzneimittelforschung; 1989 Jan; 39(1):90-3. PubMed ID: 2719748
[TBL] [Abstract][Full Text] [Related]
5. [Restorative effect of muroctasin, MDP-Lys (L 18), on leukopenia caused by anticancer chemotherapy in lung cancer--comparative study by envelope method].
Takada M; Fukuoka M; Takifuji N; Sakai N; Ryu S; Masuda N; Matsui K; Negoro S; Kusunoki Y; Tsubura E
Gan To Kagaku Ryoho; 1988 Nov; 15(11):3095-101. PubMed ID: 3142367
[TBL] [Abstract][Full Text] [Related]
6. [Activation of neutrophil function by MDP-Lys(L 18)].
Hirota M; Senju R; Kadota J; Hiratani K; Komori K; Kanda T; Hara K; Hayashi K; Tsuji Y; Watanabe K
Gan To Kagaku Ryoho; 1989 Feb; 16(2):219-24. PubMed ID: 2919891
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effect of muroctasin on experimental leukopenia induced by cyclophosphamide or irradiation in mice.
Nakajima R; Ishida Y; Yamaguchi F; Otani T; Ono Y; Nomura M; Une T; Osada Y
Arzneimittelforschung; 1988 Jul; 38(7A):986-92. PubMed ID: 3263871
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of host defense mechanism against infection by a cytokine inducer, an acyl-MDP derivative, MDP-Lys(L18) (romurtide) in mice and humans.
Azuma I; Otani T
Med Res Rev; 1994 Jul; 14(4):401-14. PubMed ID: 8084203
[No Abstract] [Full Text] [Related]
9. Restorative effect of romurtide for thrombocytopenia associated with intensive anticancer drug treatment and/or irradiation in patients with gastrointestinal cancer.
Yano K; Matsuoka H; Seo Y; Kounoe S; Saito T; Tomoda H
Anticancer Res; 1995; 15(6B):2883-7. PubMed ID: 8669883
[TBL] [Abstract][Full Text] [Related]
10. Acute and chronic polyarthritis induced by an aqueous form of 6-O-acyl and N-acyl derivatives of N-acetylmuramyl-L-alanyl-D-isoglutamine in euthymic rats and athymic nude rats.
Kohashi O; Kohashi Y; Shigematsu N; Ozawa A; Kotani S
Lab Invest; 1986 Sep; 55(3):337-46. PubMed ID: 3489128
[TBL] [Abstract][Full Text] [Related]
11. Review: inducer of cytokines in vivo: overview of field and romurtide experience.
Azuma I
Int J Immunopharmacol; 1992 Apr; 14(3):487-96. PubMed ID: 1618600
[TBL] [Abstract][Full Text] [Related]
12. [Muroctasin, a muramyl dipeptide derivative].
Sosnowska D; Dzierzbicka K; Myśliwski A; Kołodziejczyk AM
Postepy Hig Med Dosw; 1992; 46(5):521-30. PubMed ID: 1298958
[TBL] [Abstract][Full Text] [Related]
13. [Muramyl dipeptide derivative and its clinical application].
Tsubura E
Kekkaku; 1989 Nov; 64(11):731-9. PubMed ID: 2593464
[TBL] [Abstract][Full Text] [Related]
14. Effect of muramyl dipeptide and its stearoyl derivatives on resistance to Sendai virus infection in mice.
Ishihara C; Hamada N; Yamamoto K; Iida J; Azuma I; Yamamura Y
Vaccine; 1985 Dec; 3(5):370-4. PubMed ID: 2417426
[TBL] [Abstract][Full Text] [Related]
15. Activation of the cytokine network by muroctasin as a remedy for leukopenia and thrombopenia.
Furuse K; Sakuma A
Arzneimittelforschung; 1989 Aug; 39(8):915-7. PubMed ID: 2684174
[TBL] [Abstract][Full Text] [Related]
16. Effect of MDP-Lys(L18), a derivative of MDP, on enhancing host resistance against Hantaan virus infection in newborn mice.
Yoo YC; Yoshimatsu K; Hatsuse R; Tamura M; Yoshida R; Tono-oka S; Arikawa J; Azuma I
Vaccine; 1995 Oct; 13(14):1300-5. PubMed ID: 8585284
[TBL] [Abstract][Full Text] [Related]
17. Experimental and clinical studies on the effects of synthetic muramyldipeptide derivatives on viral and opportunistic infections.
Yamamura Y; Ishihara C; Hamada N; Yamamoto K; Azuma I
Methods Find Exp Clin Pharmacol; 1986 Jan; 8(1):11-4. PubMed ID: 3010013
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo effects of MDP-Lys(L18) on mouse megakaryocyte progenitor cells (CFU-Meg).
Komiya I; Kuriya S; Akahane K; Nomura T
Exp Hematol; 1992 May; 20(4):517-22. PubMed ID: 1568468
[TBL] [Abstract][Full Text] [Related]
19. Antigenicity study of muroctasin.
Yamaguchi F; Hattori H; Wagai N; Tsukada W
Arzneimittelforschung; 1988 Jul; 38(7A):1034-7. PubMed ID: 3190797
[TBL] [Abstract][Full Text] [Related]
20. Mutagenicity studies of muroctasin.
Shimada H; Hattori C; Sato T
Arzneimittelforschung; 1988 Jul; 38(7A):1031-3. PubMed ID: 3056424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
